Our very own Troy Wilson joined fellow industry leaders on the panel, Exploring the Inflation Reduction Act: Pharma’s Legal Battles and the Future of Innovation, at Fierce JPM week. The Inflation Reduction Act (IRA) became law in 2022 and Troy spoke to the specific challenges for biopharma companies and how its leaders can navigate obstacles presented by the IRA including:
- The current landscape of cancer treatments that are focused on addressing cancer at the molecular or genetic level.
- Implications on length of drug development in line with the IRA.
- Working with regulators and lawmakers to find solutions that benefit patients and create the best pathways for drug development.
Watch an excerpt from the panel to learn more about the IRA and how biotech companies are moving forward.
